Fixed dosing of oral targeted therapies is inadequate in the era of precision medicine.
Personalized dosing, based on pharmacokinetic (PK) exposure, known as therapeutic drug …

Background Oral targeted therapies show a high pharmacokinetic (PK) interpatient
variability. Even though exposure has been positively correlated with efficacy for many of …

Most anticancer agents show wide variability in pharmacokinetics (PK) and have a narrow
therapeutic index which makes fixed dosing suboptimal. To achieve the best therapeutic …

Purpose While in the era of precision medicine, the right drug for each patient is selected
based on molecular tumor characteristics, most novel oral targeted anticancer agents are …

The emergence of molecularly targeted agents in oncology has not only revolutionized the
care of cancer patients, but also changed the daily practice of medical oncologists …

The prerequisites for the successful implementation of therapeutic drug monitoring (TDM)
include high inter-subject variation, low inter-occasion variation, narrow therapeutic index …

Selecting the dose of a targeted cancer medicine that is most appropriate for a specific
individual is a rational approach to maximize therapeutic outcomes and minimize toxicity …

The prospect of precision dosing in oncology is attractive for several reasons. Many
anticancer drugs display narrow therapeutic indices, where suboptimal therapy may lead to …

Background: Oral anticancer drugs show a high interpatient variability in pharmacokinetics
(PK), leading to large differences in drug exposure. For many of these drugs, exposure has …

The purpose of this article is to acknowledge the challenges in optimizing the dosing of
oncology drugs and to propose potential approaches to address these challenges in order …